Carregant...
The views of stakeholders on controlled access schemes for high-cost antirheumatic biological medicines in Australia
BACKGROUND: In Australia, government-subsidised access to high-cost medicines is "targeted" to particular sub-sets of patients under the Pharmaceutical Benefits Scheme to achieve cost-effective use. In order to determine how this access system could be improved, the opinions of key stakeho...
Guardat en:
| Autors principals: | , , , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
BioMed Central
2007
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2231358/ https://ncbi.nlm.nih.gov/pubmed/18096055 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1743-8462-4-26 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|